Histopathological and Clinical Features as Prognostic Factors of Atypical Meningiomas

Pinar Karabagli1, Hakan Karabagli, Zekiye Mavi

  • 1Selcuk University, School of Medicine, Department of Pathology, Konya, Turkey.

Turkish Neurosurgery
|July 25, 2020
PubMed
Abstract

Insights

Clinicopathological features do not predict recurrence in atypical meningiomas (AMs). Future studies require molecular variables for better prediction of atypical meningioma progression-free survival (PFS).

Area of Science:

  • Neurosurgery
  • Pathology
  • Oncology

Background:

  • Atypical meningiomas (AMs) are rare tumors with a higher recurrence rate than typical meningiomas.
  • Predicting recurrence and progression-free survival (PFS) in AMs is crucial for patient management.

Purpose of the Study:

  • To investigate the correlation between clinicopathological prognostic parameters and recurrence development in atypical meningiomas.
  • To analyze the impact of these parameters on progression-free survival (PFS) in patients with atypical meningiomas.

Main Methods:

  • Retrospective review of 75 patients with atypical meningiomas (AMs) diagnosed between 2010 and 2019.
  • Analysis of clinicopathological parameters including age, sex, tumor location, size, resection degree, histological features, Ki67 labeling index, and invasion.
  • Univariate and multivariate analyses were performed to identify prognostic factors for recurrence and PFS.

Main Results:

  • Recurrence was observed in 20 patients, with a mean PFS of 38.9 months.
  • Univariate analysis showed several features associated with recurrence, but none were statistically significant in multivariate analysis.
  • Increased mitotic activity and brain invasion were significantly associated with PFS in multivariate analysis.

Conclusions:

  • Clinicopathological features alone are insufficient to predict recurrence in atypical meningiomas (AMs).
  • Molecular variables are likely necessary for accurate prediction of atypical meningioma recurrence and PFS.
  • Further research focusing on molecular markers is warranted for improved prognostic assessment.